Date: 2016-04-19
Type of information: Collaboration agreement
Compound: integrated small molecule pharmaceutical discovery and development services
Company: Domainex (UK) Johnson Matthey (UK)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On April 19, 2016, Johnson Matthey, a provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies and Domainex, a small-molecule drug discovery company, have announced a collaboration to provide integrated small molecule pharmaceutical discovery and development services. The focus will be on providing academic institutes, biotechnology and pharmaceutical companies across the UK and beyond with effective, simplified, rapid and reduced risk target-to-lead identification, optimisation, safety/toxicology, pre-clinical and clinical API supply services. Domainex is a leading provider of small molecule drug discovery services that complement the pre-clinical to commercial range of services provided by Johnson Matthey Fine Chemicals’ Custom Pharma Solutions offering in Europe. Through an integrated offering co-located in the Cambridge region, customers will be able to access Domainex’s target-to-lead identification and optimisation capabilities, and will then be able to transfer their projects directly to Johnson Matthey, utilising its Pharmorphix solid state services for effective salt form and polymorph identification through to process development, scale-up and non-GMP toxicology manufacture. With all activities co-located in the Cambridge area, discovery and development time and risk can be greatly minimised.
Financial terms:
Latest news:
